Literature DB >> 25970331

Correction: Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults.

.   

Abstract

Entities:  

Year:  2015        PMID: 25970331      PMCID: PMC4430515          DOI: 10.1371/journal.pone.0128167

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
There are a number of errors in Table 3. Multiple upper-case T’s were included instead of the correct lower-case, italicized t’s. Trans-vaccenic acid was incorrectly spelled as Transvaccenic acid, and Palmitelaidic acid was incorrectly written as Palmitoleic acid. Please see the correct Table 3 here.
Table 3

Range, mean and percentiles of FA concentrations (μmol/L) of plasma total lipids.

Fatty AcidMinMean±SDMax1025507590
14:0 (Myristic acid)16.263.6 ± 37.1325.729.839.254.076.2104.7
15:0 (Pentadyclic acid) t 17.8 ± 6.756.110.813.217.121.326.3
16:0 (Palmitic acid)285.41631.1 ± 459.34064.51140.21339.71569.51839.22182.2
18:0 (Stearic acid)110.2489.5 ± 124.31013.7353.3406.9474.2556.8650.9
19:0 t 4.3 ± 4.225.7 t 1.13.16.610.2
20:0 (Arachidic acid) t 4.9 ± 3.729.8 t 2.64.66.49.4
21:0 t 1.5 ± 1.910.0 t t 0.32.94.1
22:0 (Behenic acid) t 6.7 ± 5.339.0 t 3.46.09.414.0
24:0 (Lignoceric acid) t 1.4 ± 2.415.7 t t t 2.45.1
14:1 (Myristoleic acid) t 2.7 ± 4.131.3 t t t 4.27.7
15:1 c10 t 0.1 ± 0.32.7 t t t t t
16:1 c9 (Palmitoleic acid)27.7133.0 ± 67.2555.967.888.5119.5156.9211.4
17:1 c10 t 10.5 ± 7.445.2 t 6.210.714.719.1
18:1 c9 (Oleic acid)178.71285.5± 416.73210.5858.61007.11226.31472.01808.7
18:1 c11 (Vaccenic acid)11.4129.2 ± 59.5562.981.596.6114.3141.5185.1
18:1 c12 t 18.7 ± 13.6101.86.69.014.922.738.3
18:1 c13 t 3.5 ± 3.518.1 t 1.22.54.58.9
18:1 c14 t 2.2 ± 1.911.6 t 0.62.03.45.0
19:1 c10 t 0.5 ± 1.18.2 t t t t 1.9
20:1 c5 t 4.8 ± 3.126.92.23.14.25.67.6
20:1 c8 t 1.3 ± 1.810.5 t t 0.42.14.1
20:1 c11 (Gondoic acid) t 8.2 ± 4.929.52.24.88.011.114.1
22:1 c13 (Erucic acid) t 3.9 ± 5.948.0 t t t 7.112.2
24:1 c15 (Nervonic acid) t 4.0 ± 5.330.0 t t 1.86.311.8
16:1 t9 (Palmitelaidic acid) t 17.0 ± 9.165.2 t 12.117.322.028.2
18:1 t4 t 5.2 ± 5.330.7 t t 4.18.312.3
18:1 t5 (Thalictric acid) t 1.7 ± 2.919.0 t t 0.51.75.6
18:1 t6-8 (Petroselaidic acid) t 7.5 ±5.956.02.53.85.79.514.8
18:1 t9 (Elaidic acid) t 16.5 ± 11.388.06.49.013.120.032.9
18:1 t10 t 17.0 ± 11.371.16.48.813.721.832.4
18:1 t11 (Trans-vaccenic acid) t 14.0 ± 8.174.25.98.712.318.024.7
18:1 t12 t 9.6 ± 5.742.84.05.68.412.317.1
18:1 t13 or c6 t 12.5 ± 17.1175.7 t 5.79.313.921.1
18:2 tt t 3.5 ± 4.338.7 t 1.12.34.57.4
18:2 t9t12 (Linoelaidic acid) t 2.1 ± 3.020.9 t t 1.22.56.7
18:2 c9t13 t 8.5 ± 8.069.3 t 2.17.711.917.7
18:2 c9t12 t 15.4 ± 6.445.28.410.914.218.924.0
18:2 t9c12 t 9.8 ± 4.331.55.36.99.012.215.6
18:2 c9c14 t 3.0 ± 7.762.1 t t t t 10.0
18:2 c9c15 (Mangiferic acid) t 3.0 ± 3.939.1 t t 2.04.67.2
18:2 c9t11 CLA t 14.4 ± 6.242.77.510.113.317.322.4
18:2 c11t13 CLA t 2.1 ± 1.812.3 t t 2.23.04.2
18:2 t10c12 CLA t 4.3 ± 2.517.92.02.93.85.27.3
18:2 c/c CLA1 t 0.8 ± 1.38.5 t t t 1.42.6
18:2 c/c CLA2 t 0.5 ± 1.06.6 t t t t 1.9
18:2 tt CLA t 6.5 ± 4.423.2 t 3.26.59.511.9
18:2 c9c12 (LA)279.72233.8± 622.64970.51540.11853.02208.22596.02962.0
18:3 c6c9c12 (γ-linolenic acid)1.423.5 ± 13.893.39.013.820.829.441.4
20:2 c11c14 (Dihomo linolenic acid) t 13.1 ± 5.037.37.89.812.516.019.7
20:3 c8c11c14 (Homo-γ-linolenic acid)7.974.3 ± 30.4222.141.553.068.290.4113.4
20:4 c5c8c11c14 (AA)42.7393.0 ± 119.1882.8254.8313.3385.6461.4548.2
22:2 c13c16 (Docosadienoic acid) t 3.1 ± 3.318.4 t t 2.84.97.3
22:4 c7c10c13c16 (Adrenic acid) t 15.4 ± 23.0158.41.95.68.512.536.5
22:5 c4c7c10c13c16 (n-6 DPA) t 8.0 ± 5.941.1 t 4.77.410.315.1
18:3 c9c12c15 (LNA)12.054.4 ± 25.1186.929.137.948.665.487.6
18:4 c6c9c12c15 (Stearidonic acid) t 0.2 ± 0.54.3 t t t t 0.6
20:3 c11c14c17 (Dihomolinoleic acid) t 1.6 ± 2.517.9 t t t 2.94.8
20:5 c5c8c11c14c17 (EPA)4.440.3 ± 28.3215.416.023.432.447.573.3
22:3 c13c16c19 t 0.6 ± 1.915.1 t t t t 2.6
22:5 c7c10c13c16c19 (n-3 DPA) t 23.9 ± 10.088.514.017.722.127.836.5
22:6 c4c7c10c13c16c19 (DHA)7.288.8 ± 36.8237.547.862.782.0110.6138.0
Total FA1251.16947.6±1816.216225.35052.55780.46745.47947.89108.9

QALY: Quality-adjusted life years; CHD: Coronary heart disease; CKD: Chronic kidney disease; OI: Opportunistic infection; AE: Adverse event; VL: Viral load.

QALY: Quality-adjusted life years; CHD: Coronary heart disease; CKD: Chronic kidney disease; OI: Opportunistic infection; AE: Adverse event; VL: Viral load.
  1 in total

1.  Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults.

Authors:  Salma A Abdelmagid; Shannon E Clarke; Daiva E Nielsen; Alaa Badawi; Ahmed El-Sohemy; David M Mutch; David W L Ma
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

  1 in total
  3 in total

1.  NFκB/Orai1 Facilitates Endoplasmic Reticulum Stress by Oxidative Stress in the Pathogenesis of Non-alcoholic Fatty Liver Disease.

Authors:  Bingbing Zhang; Ming Li; Ying Zou; Han Guo; Bingdong Zhang; Cheng Xia; Hongyou Zhang; Wei Yang; Chuang Xu
Journal:  Front Cell Dev Biol       Date:  2019-10-02

2.  Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.

Authors:  James Turnbull; Rakesh R Jha; Catherine A Ortori; Eleanor Lunt; Patrick J Tighe; William L Irving; Sameer A Gohir; Dong-Hyun Kim; Ana M Valdes; Alexander W Tarr; David A Barrett; Victoria Chapman
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

3.  Dairy Fat Intake, Plasma Pentadecanoic Acid, and Plasma Iso-heptadecanoic Acid Are Inversely Associated With Liver Fat in Children.

Authors:  Mary Catherine Sawh; Martina Wallace; Emma Shapiro; Nidhi P Goyal; Kimberly P Newton; Elizabeth L Yu; Craig Bross; Janis Durelle; Cynthia Knott; Jon A Gangoiti; Bruce A Barshop; Jivani M Gengatharan; Noah Meurs; Alexandra Schlein; Michael S Middleton; Claude B Sirlin; Christian M Metallo; Jeffrey B Schwimmer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-04-01       Impact factor: 2.839

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.